Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03570827 · ClinicalTrials.gov registry record · Phase 2

Hypofractionated Radiation Therapy for Treating Prostate Cancer High-Risk Features Following Radical Prostatectomy

A Phase 2 study, sponsored by Mayo Clinic.

Completed
Registry status
Phase 2
Development phase
53
Enrollment target

NCT03570827: Completed Phase 2 study, sponsored by Mayo Clinic.

NCT03570827 is a Phase 2 study that has completed, run by Mayo Clinic. The registered enrollment target is 53 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03570827, a Phase 2 study, has completed, sponsored by Mayo Clinic.

COMPLETED
Registry status
Phase 2
Development phase
53 participants
Enrollment target

Study Summary

This phase II trial studies how well hypofractionated radiation therapy works in treating participants with prostate cancer high-risk features following radical prostatectomy. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects.

Interventions

  • OTHER Quality-of-Life Assessment
  • OTHER Questionnaire Administration
  • RADIATION Hypofractionated Radiation Therapy
  • DRUG Androgen Suppression

Trial Details

FieldValue
Enrollment Target 53 participants
Start Date 2018-05-14
Est. Completion 2025-05-15
Phase Phase 2

Sponsor

Mayo Clinic

2,844 total trials

What the Registry Record Tells You About NCT03570827

The ClinicalTrials.gov registry entry for NCT03570827 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 4 interventions - of which Quality-of-Life Assessment is the first listed.

NCT03570827 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03570827 about?

NCT03570827 is a clinical study titled "Hypofractionated Radiation Therapy for Treating Prostate Cancer High-Risk Features Following Radical Prostatectomy". This phase II trial studies how well hypofractionated radiation therapy works in treating participants with prostate cancer high-risk features following radical prostatectomy. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill mor...

What is the current status of trial NCT03570827?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 53 participants. The study started on 2018-05-14. Estimated completion is 2025-05-15.

What interventions are being tested in trial NCT03570827?

The interventions under investigation include: Quality-of-Life Assessment (OTHER), Questionnaire Administration (OTHER), Hypofractionated Radiation Therapy (RADIATION), Androgen Suppression (DRUG).

Who is sponsoring clinical trial NCT03570827?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.